Skip to content

Study · Randomized controlled trial · n = 9,901 · 2022

5 results

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.

Branch KRH, Dagenais GR, Avezum A, Basile J, Conget I, Cushman WC, Jansky P, Lakshmanan M, Lanas F, Leiter LA, Pais P, Pogosova N and 10 more

Show all authors

Raubenheimer PJ, Ryden L, Shaw JE, Sheu WHH, Temelkova-Kurktschiev T, Temelkova-Kurktschiev T, Bethel MA, Gerstein HC, Chinthanie R, Probstfield JL

European journal of heart failure20 Sept 2022Cited by 34 (Europe PMC)

PMID36073143 (opens in a new tab)DOI10.1002/ejhf.2670 (opens in a new tab)PepBankPUB-36073143
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In REWIND participants, dulaglutide did not significantly reduce heart failure events versus placebo.

    In plain wordsDulaglutide did not significantly reduce heart failure events compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHeart failure events
    Study

    n = 9,901

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · Median 5.4 yearsAs given in this study (human).

    Measurements

    HF events
    213 participants
    dulaglutide
    HF event proportion
    4.3%
    dulaglutide
    HF events
    226 participants
    placebo
    HF event proportion
    4.6%
    placebo
    Hazard ratio
    0.93 ratio
    dulaglutide versus placebo
    95% CI lower
    0.77 ratio
    HF hazard ratio
    95% CI upper
    1.12 ratio
    HF hazard ratio

    Source sentences

    Summary
    Of the 9901 participants studied over a median follow-up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77-1.12; p = 0.456).
    2 context sentences
    Summary · context
    We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.
    Summary · context
    In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In REWIND participants, dulaglutide marginally reduced combined cardiovascular death and heart failure events compared with placebo.

    In plain wordsDulaglutide marginally reduced cardiovascular death or heart failure events compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCardiovascular death or heart failure events
    Study

    n = 9,901

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · Median 5.4 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.88 ratio
    cardiovascular death and HF events
    95% CI lower
    0.78 ratio
    composite hazard ratio
    95% CI upper
    1 ratio
    composite hazard ratio

    Source sentences

    Summary
    Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78-1.00; p = 0.050) but unchanged in patients with and without HF at baseline (p = 0.31).
    2 context sentences
    Summary · context
    We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.
    Summary · context
    In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF.

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In REWIND participants, dulaglutide's MACE effect did not differ by baseline heart failure status.

    In plain wordsDulaglutide's cardiovascular event effect did not differ between participants with and without prior heart failure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeMACE interaction by baseline heart failure
    Study

    n = 9,901

    Comparator
    Treatment effect in participants without baseline HF
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Interaction p-value (MACE)
    0.44 p-value
    baseline HF versus no baseline HF
    Interaction p-value (HF events)
    0.19 p-value
    baseline HF versus no baseline HF

    Source sentences

    Summary
    In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF (p = 0.44 and 0.19 for interaction, respectively).
    2 context sentences
    Summary · context
    We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.
    Summary · context
    In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In REWIND participants, dulaglutide's heart failure event effect did not differ by baseline heart failure status.

    In plain wordsDulaglutide's heart failure event effect did not differ between participants with and without prior heart failure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHeart failure event interaction by baseline heart failure
    Study

    n = 9,901

    Comparator
    Treatment effect in participants without baseline HF
    Outcome group
    Heart function · Cardiovascular

    Measurements

    Interaction p-value
    0.19 p-value
    HF events, baseline HF versus no baseline HF

    Source sentences

    Summary
    In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF (p = 0.44 and 0.19 for interaction, respectively).
    2 context sentences
    Summary · context
    We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.
    Summary · context
    In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In REWIND participants, dulaglutide's cardiovascular death and heart failure composite effect did not differ by baseline heart failure status.

    In plain wordsDulaglutide's composite outcome effect did not differ between participants with and without prior heart failure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeComposite outcome interaction by baseline heart failure
    Study

    n = 9,901

    Comparator
    Treatment effect in participants without baseline HF
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Interaction p-value
    0.31 p-value
    CV death or HF events, baseline HF versus no baseline HF

    Source sentences

    Summary
    Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78-1.00; p = 0.050) but unchanged in patients with and without HF at baseline (p = 0.31).
    2 context sentences
    Summary · context
    We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.
    Summary · context
    In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.